🇺🇸 Thallous Chloride T1-201 in United States
5 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 5
Most-reported reactions
- Fatigue — 1 report (20%)
- Pain — 1 report (20%)
- Pneumonia — 1 report (20%)
- Tachycardia — 1 report (20%)
- Weight Decreased — 1 report (20%)
Other Cardiovascular approved in United States
Frequently asked questions
Is Thallous Chloride T1-201 approved in United States?
Thallous Chloride T1-201 does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Thallous Chloride T1-201 in United States?
GE Healthcare is the originator. The local marketing authorisation holder may differ — check the official source linked above.